Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Electronic screening tool to triage teenagers and risk of substance misuse

  • Mortality rates increase due to extreme heat and cold

  • Diverse boards pay more dividends, take fewer risks, study finds

  • Help your infant or toddler cope with stressful events

  • Autistic brain less flexible at taking on tasks

  • Social origins of intelligence in the brain

  • Brand-specific television alcohol ads a significant predictor of brand consumption among underage youth

  • Brainwaves can predict audience reaction of television programming

  • Watching neurons fire from a front-row seat

  • Vision-correcting display makes reading glasses so yesterday

  •